RailRiders Unveil New Collaboration with Wallenpaupack Brewing Company The Scranton/Wilkes-Barre RailRiders are pleased to announce a new collaboration with Wallenpaupack Brewing Company in 2024, the Home Half Hazy Pale Ale. The Hawley, PA-based brewery is introducing a new beer into its catalog and the offering will be available at PNC Field this season. Coming in with 5.5% Alcohol by Volume, 30 International Bitterness Units and a generous addition of Citra and Mosaic hops, fans can expect a juicy blast of citrus, tropical fruit and melon from this sessionable pale ale while taking in nine innings of action. “We are thrilled to welcome this custom brew from Wallenpaupack Brewing Company into our starting lineup,” said Katie Beekman, General Manager of the Scranton/Wilkes-Barre RailRiders. “This tremendous partnership has provided our fanbase with their well-known local offerings and we know the Home Half Hazy Pale Ale will quickly become a fan favorite at PNC Field. We always look for ways to grow with our partners and this is a natural next step with Wallenpaupack Brewing Company.” “In baseball vernacular, the Home Half is the part of the inning where the home team is up to bat and we thought that it was a great message that no matter what a fan’s Major League team might be, people from the Scranton/Wilkes-Barre area truly embrace the RailRiders as their home team and PNC Field as their home ballpark,” said Brad Beneski, Wallenpaupack Brewing Company’s Director of Business Development. “And, so we wanted to find a way to make every visit to the ballpark as immersive of a local experience as possible with an official beer for the home crowd.” Wallenpaupack Brewing Company and the Scranton/Wilkes-Barre RailRiders are entering their second year of a four-year partnership that gives the award-winning, local brewery naming rights to a craft beer stand on the third base side of the team’s concourse where fans can find a variety of draft and canned options including their flagships, current seasonals, and now an exclusive collaboration with the team. The brewery also conducts social media contests to give away tickets for each home stand. “As community members, we know how fortunate we are to have a team like the RailRiders and a space like PNC Field right in our backyard, so to be a part of the experience is an honor in which we take a lot of pride,” Beneski added. “And with our brewpub being an easy trip from the ballpark, we’ve even had a fair amount of baseball fans make the trek to see our brewery and taproom for themselves.” Please drink responsibly! The RailRiders open their 2024 season on March 29 with a three-game weekend set at Buffalo. The home opener is set for April 2 at 6:35 P.M. as the Syracuse Mets come to PNC Field. Season tickets, mini plans and the flex plan are all available now. For more information or to purchase tickets, contact the RailRiders front office at (570) 969-BALL or visit swbrailriders.com.
Tobyhanna Army Depot Collaborating with U.S. Army Information Systems Employees at Tobyhanna Army Depot are leading the charge to connect warfighters in the field with their leadership back at home. The depot is now collaborating with the U.S. Army Information Systems Engineering Command to lead the Mission Command Facility (MCF) workload across the Department of Defense. The MCF effort is an offshoot of the Home Station Mission Command Center effort, which established and modernized joint operations mission centers around the world. Similar to a situation room, the facilities are outfitted with high-end teleconferencing equipment such as projectors, video monitors, microphones, and speakers for real-time communication, visibility and decision-making. Taking over the mission represents a classic opportunity to meet a customer need and own a niche market, according to Robert Hagenbaugh. “Although the formal HSMCC program concluded, units across the world were eager to get their own command centers to increase communication,” he said. “Tobyhanna quickly stood up our own program to fill a gap in the market, and we have a heavy demand for these state-of-the-art installations.” Hagenbaugh is an engineering technician in the Production Engineering Directorate. Tobyhanna’s initial support for HSMCCs provided electricians and equipment installers. The quality product provided by those teams led to an expanded scope of work, which included custom cabinetry, wood fabrication, networking support, wireless installation, and full-spectrum engineering support – all of which has endured through the new MCF program. Hagenbaugh noted positive word of mouth was a big driver in the workload’s expansion. “Our customers love us. I’m proud to say we have never left a job with an unhappy customer. That level of work speaks for itself – and every happy customer leads to another opportunity for this workload.” A MCF mission begins with a site survey, where engineering personnel develop exact customer needs. Personnel then develop the installation proposal, acquire equipment once the proposal is approved and assemble the installation team. To accomplish this broad scope of work, the MCF program requires support from a cross-functional group of employees across the depot. Mission teams include employees from a variety of Tobyhanna organizations, to include C4ISR, Production Engineering and Systems Integration and Support. The teams also have support back on-post at Tobyhanna from Production Management and other mission support organizations. MCF installations are part of a bigger push across the services to modernize facilities and increase communication stability. “The Army now operates in a multi-domain battlefield. The MCF updates/ installations gives joint Commanders the latest technologies to monitor and execute missions real-time, every single day,” said Hagenbaugh. Because of the high demand for the MCFs and the complex nature of the mission, volunteers are always needed, said Engineering Technician Patrick Mullen. “We are always looking for members of Team Tobyhanna willing to travel the world in support of this dynamic workload – specifically those with audio-visual, telecommunications, or information technology backgrounds. Desirable certifications and/or trainings include those from Avixa, BICSI, and Crestron. We welcome all qualified members of Team Tobyhanna who want to be a part of the MCF mission team!” Ronald Kolment, Chief of the SATCOM Integration and Testing Engineering Branch, lauded the entire team that supported the MCF workload. “This is a great team, and I’m very proud of the work that they do.” Upcoming MCF missions will take place in Alaska, Florida, Hawaii, Japan, Korea, and Texas. Current depot employees interested in volunteering for an MCF mission should contact the MCF Coordinator at (570) 615-8087. MCFs are a critical part of warfighter readiness, and the mission directly aligns with Tobyhanna’s long-range strategic plan, TOBY2035, which has four focus areas: Investing in Our People, C5ISR Readiness, Shape the Future and Strategic Communications. TOBY2035 aims to posture the depot for success in the coming years as the Department of Defense’s premier worldwide C5ISR readiness provider. Tobyhanna Army Depot is a recognized leader in providing world-class logistics support for command, control, communications, computers, cyber, intelligence, surveillance and reconnaissance (C5ISR) systems across the Department of Defense. Tobyhanna’s Corporate Philosophy, dedicated work force and electronics expertise ensure the depot is the Joint C5ISR provider of choice for all branches of the Armed Forces and industry partners. Tobyhanna’s unparalleled capabilities include full-spectrum logistics support for sustainment, overhaul and repair, fabrication and manufacturing, engineering design and development, systems integration, post production software support, technology insertion, modification, foreign military sales and global field support to our joint warfighters. About 3,100 personnel are employed at Tobyhanna, which is located in the Pocono Mountains of northeastern Pennsylvania. Tobyhanna Army Depot is part of the U.S. Army Communications-Electronics Command. Headquartered at Aberdeen Proving Ground, Maryland, the command’s mission is to empower the Soldier with winning C5ISR capabilities.
FDA Grants Breakthrough Device Designation to Tempus in Collaboration With Geisinger Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter. Breakthrough Designation entitles the platform to an expedited regulatory process. The platform was designated as a Breakthrough Device for use with patients 40 years of age and older, without pre-existing or concurrent AFib or atrial flutter, and who are at elevated risk of stroke based on a commonly used clinical stroke risk assessment tool (i.e., CHA₂DS₂-VASc score of ≥4). The device analyzes the results of a 12-lead ECG administered as part of routine care to provide clinicians with insight into a patient’s risk of future atrial fibrillation and/or atrial flutter events. When interpreted in conjunction with other available clinical information this can support clinicians in pursuing early and proactive diagnoses of AFib and atrial flutter with the goal of enabling improved clinical management of these conditions and their associated health risks. AFib, which is a leading cause of stroke, is frequently unrecognized and untreated. Currently, there are no available devices to help physicians identify asymptomatic patients without a known history of cardiac arrhythmia who are at increased risk of future AFib, which carries other health risks including stroke and death. The Tempus ECG Analysis Platform is tackling that challenge by analyzing results of a widely used clinical test, the 12-lead ECG, with software that identifies patients at increased risk of developing AFib or atrial flutter within the next 12 months. A team of Geisinger and Tempus scientists and clinicians recently published a related study in Circulation, which showed that artificial intelligence can predict risk of new AFib and AFib-related stroke. For this research study, the combined team of data scientists and medical researchers used 1.6 million ECGs to train a deep neural network to predict, among people without a previous history of AFib, who would develop it within the next 12 months. In people with no history of AFib that went on to have an AFib-related stroke, nearly two thirds would have been predicted to be at high-risk before the stroke. “In granting our request for Breakthrough Device designation, the FDA is helping bring the power of artificial intelligence to patients, with new, smarter tools that can support clinicians in predicting future clinical events,” said Joel Dudley, Ph.D., Chief Scientific Officer of Tempus. “Every year, hundreds of millions of ECGs are performed in the U.S. to detect cardiac abnormalities as part of routine clinical care. We are making ECGs smarter so that they can also identify the risk of future clinical events of interest, such as AFib, thus enabling clinicians to act earlier in the course of disease and improve patient outcomes.” “Much of what we do as clinicians relies on predicting the future. Geisinger and Tempus are working together to make smarter, more accurate predictions about future clinical events,” said Brandon Fornwalt, MD, Ph.D., Chair of Geisinger’s Department of Translational Data Science and Informatics. “This is ultimately about helping patients and fulfilling the promise of precision health by supporting clinical decision making with additional patient-specific information, and we are excited that the FDA recognizes the importance of this work.” The FDA’s Breakthrough Device Program was established to accelerate the availability of transformative medical devices to patients and healthcare providers by speeding up their development, assessment and review, while preserving the statutory standards for premarket review and authorization. Designation is awarded to innovative devices that provide more effective diagnosis or treatment of life-threatening conditions and that offer significant advantages over the existing standard of care, where no approved or cleared alternatives exist, and where early device availability is in patients’ best interests.
